Form 4: Celularity Director LeVien Boosts Stake with RSU Grant

Celularity Inc. Director Vincent LeVien acquired 28,847 restricted stock units, increasing his beneficial ownership to 153,847 shares.

Summary

• Vincent LeVien, a Director of Celularity Inc. (CELU), acquired 28,847 shares of Class A Common Stock.
• The transaction occurred on January 12, 2026, and was an acquisition (Code A) at a price of $0 per share.
• These shares represent Restricted Stock Units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU grants the right to receive one share of the Issuer's Class A common stock.
• The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, contingent on Mr. LeVien's continuous service.
• Following this transaction, Mr. LeVien beneficially owns a total of 153,847 shares, which includes the newly granted 28,847 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's an equity grant (not an open market purchase), it increases a director's stake, aligning their interests with shareholders. There are no negative implications from this specific filing.

Positives

• The acquisition of restricted stock units by a director can signal alignment of interests between management and shareholders.
• The grant is part of an established equity incentive plan, indicating a structured approach to executive compensation.

Risks

• The vesting of the restricted stock units is subject to Vincent LeVien's continuous service with Celularity Inc., meaning the shares are not immediately owned outright and could be forfeited if service terminates before vesting.

Future Outlook

The future ownership of the 28,847 restricted stock units by Director Vincent LeVien is contingent upon his continuous service with Celularity Inc. until the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting.

Industry Context

Insider transactions, particularly equity grants, are a common component of executive and director compensation packages across various industries, aiming to align the interests of company leadership with long-term shareholder value. This specific grant is consistent with typical practices in the biotechnology and healthcare sectors for retaining and incentivizing key personnel.

Corporate Governance

Related Party Transactions

• The acquisition of restricted stock units by Director Vincent LeVien from Celularity Inc. constitutes a related party transaction, as it involves an equity grant from the company to an insider.

Stakeholder Impact

• Shareholders: May view the increased beneficial ownership by a director as a positive sign of confidence and alignment with long-term company performance.
• Employees: The existence of an equity incentive plan (2021 Plan) suggests a broader framework for employee and director compensation, potentially impacting morale and retention.

Next Steps

• The granted Restricted Stock Units (RSUs) will vest on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Celularity, CELU, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Ownership, Stock Compensation